Revvity, Inc. (RVTY)

113,23 +1,21 (+1,08%) Al cierre: 04:00PM EDT

Revvity, Inc.

940 Winter Street
Waltham, MA 02451
United States
781 663 6900
https://www.revvity.com

Sector(es): Healthcare
Sector: Diagnostics & Research
Empleados a tiempo completo: 11.000

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Prahlad R. Singh Ph.D.	CEO, President & Director	1,43M	N/A	1965
Mr. Maxwell Krakowiak	Senior VP & CFO	631,11k	N/A	1990
Mr. Tajinder S. Vohra	Senior Vice President of Global Operations	574,08k	N/A	1966
Mr. Joel S. Goldberg	Senior VP of Administration, General Counsel & Secretary	720,74k	N/A	1969
Ms. Miriame Victor	Senior VP & Chief Commercial Officer	555,4k	N/A	1982
Mr. Andrew Okun	VP, Chief Accounting Officer & Treasurer	N/A	N/A	1970
Mr. Bryan A. Kipp	Senior Vice President of Technology & Licensing	N/A	N/A	N/A
Ms. Madhuri Hegde FACMG, Ph.D.	Senior VP & Chief Scientific Officer	N/A	N/A	N/A
Mr. Stephen Barr Willoughby	Senior VP of Investor Relations & Head of ESG	N/A	N/A	N/A
Ms. Magali Four	Senior VP & Chief People and Culture Officer	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Gobierno corporativo

El ISS Governance QualityScore de Revvity, Inc., a día 1 de mayo de 2024, es 8. Las puntuaciones base son Auditoría: 10; Tablero: 3; Derechos de los accionistas: 8; Compensación: 7.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.